Literature DB >> 17119963

Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome.

P R J Ames, C Tommasino, G Fossati, G Scenna, V Brancaccio, F Ferrara.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119963     DOI: 10.1007/s00277-006-0226-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  6 in total

1.  Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis.

Authors:  Rubens Costa; Salman Fazal; Robert B Kaplan; Joel Spero; Ricardo Costa
Journal:  Clin Rheumatol       Date:  2010-06-17       Impact factor: 2.980

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 3.  Use of rituximab in the antiphospholipid syndrome.

Authors:  Deepak Kumar; Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 4.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 5.  The potential utility of B cell-directed biologic therapy in autoimmune diseases.

Authors:  D G Arkfeld
Journal:  Rheumatol Int       Date:  2007-10-24       Impact factor: 2.631

Review 6.  Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?

Authors:  Ilaria Mormile; Francescopaolo Granata; Alessandra Punziano; Amato de Paulis; Francesca Wanda Rossi
Journal:  Biomedicines       Date:  2021-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.